The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year.
Introduction
According to the recent American Heart Association Heart Disease and Stroke Statistics, acute coronary syndromes (ACS) accounted for approximately 1.6 million hospitalizations including primary and secondary discharge diagnoses in US hospitals in 2004. (NSTE-ACSs) comprise nearly two-thirds of the overall ACS population. There have been recent advances in percutaneous coronary intervention (PCI) techniques and antithrombotic regimen used to treat patients with ACS. 2 Available evidence supports a treatment strategy of earlier angiography and PCI, preferably performed within 24 h of presentation in patients with NSTE-ACS. 3 The use of invasive treatment strategy in these patients has been associated with a constant quest to optimize adjunctive antithrombotic therapy. Platelet glycoprotein IIb/IIIa receptor inhibitors, 4 -7 clopidogrel, 8 and their combination 9 have been tested in addition to aspirin and heparin in patients with NSTE-ACS undergoing PCI. Although glycoprotein IIb/IIIa inhibitors are more powerful inhibitors of platelet aggregation than are thienopyridines, benefit of administration of glycoprotein IIb/IIIa inhibitors to patients treated with thienopyridines remains unproven, at least in patients with low-to-intermediate risk undergoing PCI. 10, 11 There is limited information regarding the efficacy of combined use of glycoprotein IIb/IIIa inhibitors and clopidogrel in patients with NSTE-ACS undergoing PCI.
The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial (ISAR-REACT 2) was a multicentre, randomized, double-blind, placebo-controlled trial that investigated whether abciximab provides incremental benefit in high-risk patients with NSTE-ACS undergoing urgent PCI after pre-treatment with 600 mg clopidogrel at least 2 h before the procedure. The study showed that abciximab reduced the composite 30-day endpoint of death, myocardial infarction, and target vessel revascularization by 25%. 9 However, controversy exists about whether the benefits of abciximab extend beyond the first 30 days after a PCI procedure, especially in patients pre-treated with and receiving long-term thienopyridines for an NSTE-ACS. Thus, we performed 1-year follow-up to investigate whether benefits of abciximab are maintained at 1 year after PCI in high-risk patients with NSTE-ACS enrolled in the ISAR-REACT 2 trial.
Methods Patients
The ISAR-REACT 2 trial study protocol has been previously published. 9 In brief, the trial was conducted between 
Details of study protocol
All patients received 600 mg clopidogrel at least 2 h before the PCI, as well as 500 mg aspirin. After a decision to perform PCI was made, patients were randomly assigned in a double-blind manner to receive either abciximab or placebo using sealed opaque envelopes containing the block randomization sequence for each participating centre. Block sizes were not revealed to investigators. Patients in the abciximab arm received a bolus of 0.25 mg/kg weight abciximab, followed by an infusion of 0.125 mg/kg/min (a maximum of 10 mg/min) for 12 h and a 70 U/kg bolus of heparin intravenously. Patients in the placebo arm received a bolus and a 12 h continuous infusion of placebo as well as a 140 U/kg bolus of intravenous heparin. Double blinding was achieved by using identically appearing vials in both study groups. Coronary stents were used in nearly 94% of the patients. Post-interventional antithrombotic therapy consisted of aspirin 100 -325 mg indefinitely and clopidogrel 75 mg twice daily for the remainder of the hospitalization up to 3 days followed by 75 mg a day recommended for at least 6 months. Other cardiac medications were prescribed at discretion of the patient's physician. Other details of the study protocol were reported in the primary publication. 9 The local research coordinators collected data and forwarded them to the Data Coordinating Centre.
Follow-up, definitions, and outcomes
The primary outcome of this analysis was the combined incidence of death, myocardial infarction, or target vessel revascularization 1 year after randomization. The composite of death or myocardial infarction was the secondary outcome. Information on deaths was obtained from hospital records, death certificate, or phone contact with relatives of the patient or attending physicians. The diagnosis of myocardial infarction was established in the presence of typical chest pain accompanied by either the appearance of pathological Q-waves in two or more contiguous electrocardiographic leads or elevation of creatine kinase level or its MB isoenzyme to at least three times the upper limit of normal. Target vessel revascularization was defined as coronary bypass surgery or repeat PCI involving the target vessel performed in the presence of restenosis-induced symptoms or signs of myocardial ischaemia. All patients were either seen by their physician or interviewed by phone at 30 days, 6 months, and 1 year after procedure; patients with cardiac complaints underwent a complete clinical, electrocardiographic, and laboratory check-up.
All events were adjudicated and classified by an adjudication committee blinded to assigned treatment throughout the interval of follow-up.
Statistical analysis
Data are presented as mean+standard deviation or as counts or proportions (% 
Results
Baseline characteristics of the patients have been reported in the primary publication. 9 None of the characteristics differed significantly among patients treated by abciximab or placebo.
Clinical outcome at 1 year
Mean follow-up was 355.2 + 31.1 days in the group treated with abciximab vs. 355.4 + 31.8 days in the group treated with placebo (P ¼ 0.88), with 2.9% of patients in the abciximab group and 2.3% of patients in the placebo group (P ¼ 0.40) being followed up for less than 11 months. The 1-year incidence of primary outcome-death, myocardial infarction, or target vessel revascularization-was 23.3% (n ¼ 234) in the abciximab group vs. 28.0% (n ¼ 281) in the placebo group (RR 0.80, 95% CI 0.67-0.95, P ¼ 0.012; Figure 1 ). The combined incidence of death or myocardial infarction was 11.6% (n ¼ 117) among patients treated with abciximab vs. 15.3% (n¼154) among patients treated with placebo (RR 0.74, 95% CI 0.59-0.94, P ¼ 0.015) (Figure 2 ). There were 45 deaths among patients who received abciximab and 49 deaths among patients who received placebo (1-year incidence 4.5 and 4.9%, respectively, RR 0.91, 95% CI 0.61-1.37, P ¼ 0.66) (Figure 3) . Target vessel revascularization was required in 137 patients (13.2%) who received abciximab vs. 164 patients (16.2%) who received placebo (RR 0.83, 95% CI 0.67-1.02, P ¼ 0.07) ( Table 1) ; it was coronary artery bypass surgery in 10 patients in the abciximab group and 16 patients in the placebo group (1.0 vs. 1.6%, P ¼ 0.23).
In the ISAR-REACT 2 trial, three subsets of patients had been pre-specified: increased troponin level at baseline (.0.03 mg/L), presence of diabetes, and duration of clopidogrel pre-treatment. In the current study, the efficacy of abciximab was also assessed in subsets of patients according to sex or age younger or older than 67 years (median age). The 1-year incidence of the primary outcome and the RR related with the assignment to abxicimab therapy or placebo in the entire group of patients and prespecified groups are shown in Figure 4 . The effect of abciximab was statistically significant in younger patients (,67 years of age), men, non-diabetic patients, and those with a clopidogrel loading interval of .3 h. No significant interaction with abciximab regarding the primary outcome for any of the analysed variables was observed. The combined incidence of death or myocardial infarction was also assessed in various subgroups as well ( Figure 5 ). There was a significant interaction between age and abciximab regarding the composite of death or myocardial infarction, demonstrating a preferential beneficial effect of abciximab in younger patients. A trend for an interaction between sex and abciximab, disclosing a more favourable effect in men in reducing the composite of death or myocardial infarction, was also observed ( Figure 5 ). 
Abciximab effect and troponin level
Baseline elevated troponin (.0.03 mg/L) was observed in 1049 patients (513 patients received abciximab and 536 patients received placebo). The remaining 973 patients (499 patients received abciximab and 474 patients received placebo) had troponin levels of 0.03 mg/L. One-year outcomes in the subgroups with and without elevated troponin are shown in Table 2 .
Among patients with an elevated troponin, the 1-year incidence of the primary outcome was 28.6% in the abciximab group vs. 33.3% in the placebo group (RR 0.82, 95% CI 0.66-1.02, P ¼ 0.07); among patients without an elevated troponin, the 1-year incidence of the primary outcome was 17.8% in the abciximab group vs. 22.0% in the placebo group (RR 0.79, 95% CI 0.59-1.05, P ¼ 0.10). The combined incidence of death or myocardial infarction was 17.2% in the abciximab group vs. 22.1% in the placebo group (RR 0.76, 95% CI 0.58-0.99, P ¼ 0.047) among patients with an elevated troponin and 5.8% in the abciximab group vs. 7.7% in the placebo group (RR 0.76, 95% CI 0.49 -1.24, P ¼ 0.27) among patients without an elevated troponin. The estimates (derived by the Kaplan-Meier method to account for censored data) of individual components of the primary outcome are shown in Table 2 . Myocardial infarction in patients with an elevated troponin and target vessel revascularization in patients without elevated troponin generated most of the difference in favour of abciximab in the incidence of the primary outcome at 1 year.
Discussion
In this study, we assessed the 1-year clinical outcome of patients enrolled in the ISAR-REACT 2 trial, in which abciximab was compared with placebo in high-risk patients with an NSTE-ACS undergoing PCI after pre-treatment with 600 mg clopidogrel. The main finding is that the beneficial effects of abciximab observed at 30 days are maintained 1 year after PCI procedure. placebo. An analysis of survival curves reveals that benefit by abciximab in the overall population had already been secured within the first 30 days. The parallel course of survival curves depicting the incidence of events in groups with abciximab or placebo beyond the 30-day time point shows that initial benefits of abciximab over placebo are kept relatively constant and thus are maintained up to 1-year of follow-up. Although the 30-day risk was significantly reduced by abciximab only in patients with an elevated troponin level, 9 the present analysis shows that both patients with and without an elevated troponin level appear to benefit from abciximab at 1 year in terms of major adverse cardiac events. Separate analyses showed that all three components of the primary outcome-death, myocardial infarction, or target vessel revascularization-were reached less often among patients assigned to abciximab than placebo by 1 year after PCI procedure. Furthermore, the subgroup analysis showed that abciximab use was associated with risk reduction in several subgroups of patients. However, the lack of a significant interaction between variables of interest and abciximab regarding 1-year incidence of major adverse cardiac events supports a relatively consistent beneficial effect of abciximab across subgroups. In the primary publication, subgroups of patients according to the presence of troponin status, diabetes, and clopidogrel loading interval have been pre-specified for a 30-day analysis. 9 As with 30-day outcome, the abciximab efficacy in reducing 1-year incidence of major adverse cardiac events appears to depend little on the interval between clopidogrel loading and PCI, although it should be emphasized that the duration of pre-treatment was longer than 2 h in all patients, as required by the protocol. Previous analyses of the ISAR-REACT 2 trial demonstrated that abciximab efficacy in reducing short-term (30-day) incidence of adverse cardiac events in patients with NSTE-ACS undergoing PCI after pre-treatment with aspirin and clopidogrel is age 12 and sex 13 dependent. The present data appear to corroborate these previous findings, demonstrating that age-and sex-dependent efficacy of abciximab is still evident One-year clinical outcomes with abciximab at 1 year after PCI procedure. With regard to the 1-year incidence of the composite of death or myocardial infarction (ischaemic complications), patients with an elevated troponin level at the time of PCI, as well as those with rest pain and ST-segment shifts without an elevated troponin level, appear to benefit from abciximab. In patients with an elevated troponin, the use of abciximab was associated with a reduction in the incidence of myocardial infarction; in patients without elevated troponin, the use of abciximab was associated with a reduction in the incidence of target vessel revascularization. However, as we have no detailed information on urgent and non-urgent revascularization procedures beyond 30 days from the index procedure, we cannot offer a clear-cut answer whether this impact of abciximab on target vessel revascularization reflects a preferential reduction in the rate of urgent revascularizations, as previously demonstrated. 14 Finally, because a subgroup analysis suffers from a limited number of patients/events, the possibility that preferential reduction in the rate of target vessel revascularization in patients without an elevated troponin level could be a chance finding cannot be excluded. Large-scale studies have confirmed the ability of glycoprotein IIb/IIIa receptor inhibitors to reduce the incidence of major adverse cardiac events in patients undergoing PCI. 15, 16 Durable benefit of glycoprotein IIb/IIIa receptor inhibitors at 6 months and 1 year after coronary stenting has also been reported.
14,17
The uniqueness of the present findings relates to two observations: in high-risk patients with NSTE-ACS undergoing a PCI after pretreatment with 600 mg clopidogrel, the benefit of abciximab seen at 30 days extended up to 1 year; and patients with NSTE-ACS presenting with rest pain and ST-segment shifts, but without an elevated troponin and pre-treated with 600 mg clopidogrel, seem to benefit from abciximab within the first year of follow-up after a PCI procedure. In contrast, the impact of abciximab in low-to-intermediate risk patients undergoing PCI after pretreatment with 600 mg clopidogrel has been evaluated, and no clinically measurable benefit of abciximab either in the 30-day 10,11 or 1-year outcomes 18 has been reported. The present study, taken together with earlier studies, suggests that powerful antithrombotic activity is required in high-risk patients with NSTE-ACS.
-21
The current study supports the finding that the benefit of abciximab in patients with NSTE-ACS undergoing PCI is sustainable at 1 year. Other studies have observed a late incremental benefit of abciximab in patients undergoing a PCI. 22 , 23 The results of subgroup analyses, however, should be interpreted with caution, because they are subject to the influence of limited power and multiple testing. Obviously, they need confirmation from specifically designed studies in the future. Further analyses are required to clarify whether there is an interaction between abciximab and type of stent, i.e. bare metal or drug-eluting stents with regard to later ischaemic events (myocardial infarction potentially due to stent thrombosis) or target vessel revascularization (potentially due to restenosis).
In conclusion, in patients with NSTE-ACS undergoing PCI after pre-treatment with 600 mg clopidogrel, the beneficial effects of abciximab in the reduction of major adverse cardiac events are maintained at 1 year after procedure.
